Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Effect of Rifaximin Treatment in Bloating Predominant Functional Bowel Disorders: A Randomized Double-blind Placebo-Controlled Trial With Gut Microbiota and Intestinal Gas Analysis

NCT07522255 is registered in ClinicalTrials.gov with Mahidol University as lead sponsor.

NCT NCT07522255
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07522255 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Effect of Rifaximin Treatment in Bloating Predominant Functional Bowel Disorders: A Randomized Double-blind Placebo-Controlled Trial With Gut Microbiota and Intestinal Gas Analysis
Lead sponsor
Mahidol University
Phase
Phase 3
Overall status
Not yet recruiting
Start date
April 30, 2026
Completion date
December 31, 2027
Enrollment
78 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bloating, constipation, functional bowel disorder, irritable bowel syndrome, rifaximin